Summit Therapeutics (SMMT) Projected to Post Quarterly Earnings on Tuesday

Summit Therapeutics (NASDAQ:SMMT) is anticipated to release its earnings data before the market opens on Tuesday, February 18th. Analysts expect Summit Therapeutics to post earnings of ($0.08) per share for the quarter.

Summit Therapeutics Stock Up 1.9 %

SMMT stock opened at $20.50 on Tuesday. The firm has a market cap of $15.12 billion, a PE ratio of -73.21 and a beta of -0.88. The business has a 50 day moving average of $19.30 and a 200-day moving average of $18.33. Summit Therapeutics has a 12-month low of $2.10 and a 12-month high of $33.89.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on SMMT shares. HC Wainwright restated a “buy” rating and issued a $44.00 price objective on shares of Summit Therapeutics in a research note on Tuesday, January 21st. Jefferies Financial Group initiated coverage on shares of Summit Therapeutics in a report on Friday, December 6th. They set a “buy” rating and a $31.00 price objective for the company. Wells Fargo & Company started coverage on shares of Summit Therapeutics in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $30.00 price objective on the stock. Truist Financial started coverage on shares of Summit Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $35.00 price target for the company. Finally, JMP Securities initiated coverage on Summit Therapeutics in a research note on Monday, November 4th. They issued a “market outperform” rating and a $32.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $33.57.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.